Skip to content
Companies

CardioNexa

LDL management service for heart attack and stroke patients

Raised to date

$300K

of $300K offered across 1 Form D filing

Investors
2
Last filed
Mar 30, 2026

About

CardioNexa is a Newton, Massachusetts healthcare technology company building AI-powered clinical optimization infrastructure for cardiovascular disease prevention. It targets the secondary-prevention gap: patients who have already had a heart attack, stroke, or stent but never reach their LDL-C goal. Its clinical engine reviews an entire ASCVD population against current ACC/AHA guidance and produces a prioritized care-team workqueue with a recommended next step, follow-up interval, and pre-drafted documentation for each patient. The company was co-founded by a cardiac surgeon and a technologist and says it plans to expand beyond lipids into hypertension, heart failure, and anticoagulation.

Sold as a managed service rather than software: CardioNexa's own clinical team does the population review and outreach work instead of asking a practice to adopt another portal, so there is no implementation burden on the cardiology group.

Funding

  • EquityFiled Mar 30, 2026Form D
    $300K/ $300K

Product

LipidNova

Clinical decision support / managed clinical service

A managed lipid management service for ASCVD populations that identifies patients not meeting LDL-C targets, ranks them by clinical urgency, and delivers specific therapy recommendations aligned to 2026 ACC/AHA guidelines on an 8-week follow-up cycle.

  • Prioritized patient workqueue ranked by clinical urgency
  • Guideline-based therapy recommendations aligned to 2026 ACC/AHA guidance, targeting LDL-C <55 mg/dL for very high-risk patients
  • Daily digest with one-click actions such as logging calls and faxing prior authorizations

Built for

Cardiology practices, health systems, and pharmacy teams managing ASCVD patient populations

People on file